** Biocon BION.NS climbs 4.4% to 332.80 rupees
** Drugmaker's unit Biocon Biologics gets marketing access for its immunotherapy drug Yesintek - Biocon's biosimilar for Janssen Biotech's Stelara - in the U.S.
** The therapy, chemically called ustekinumab, is used for treating patients with chronic plaque psoriasis
** Stock rated "buy" on avg; median PT is 400 rupees, per data compiled by LSEG
** Session's gains trim BION's YTD losses to 8.9%
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。